NSE: EPIGRAL · BSE: 543332 · ISIN INE071N01016
Epigral Limited stock analysis
Epigral Limited ranks #2197 in the TickerSutra evidence-ranked universe with a score of 48/100 and 95% data confidence. The latest captured fundamentals show ROCE of 15.3%, quarterly sales growth of 16.3% and quarterly profit growth of -38.2%.Avoid / exit review
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.26×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Operating margin has compressed materially
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹1,551cr | ₹510cr | ₹253cr | 33.0% |
| 2023 | ₹2,188cr | ₹689cr | ₹353cr | 31.0% |
| 2024 | ₹1,929cr | ₹481cr | ₹196cr | 25.0% |
| 2025 | ₹2,550cr | ₹711cr | ₹357cr | 28.0% |
| 2026 | ₹2,527cr | ₹567cr | ₹333cr | 22.0% |
| TTM | ₹2,626cr | ₹583cr | ₹272cr | 22.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
In parallel, the Company strengthened multiple The transition also supported the Company’s positioning towards greater market leadership in key segments, supported by scale, reliability and product quality. Higher volumes are expected to improve fixed cost absorption and enhance export competitiveness, strengthening capacity utilisation. Overall, while near-term cycles could influence capacity utilisation, the combin
Looking ahead, hydrogen peroxide is also expected to see increasing adoption in solar and semiconductor manufacturing, where high-purity chemicals are critical. The Indian market for both CMS and hydrogen peroxide is expected to grow at a CAGR of approximately 10% to 12%, supported by: Strong expansion in the pharmaceutical sector, driven by rising global demand for generics Increasing demand for agrochemicals, s
While short-term variations in demand or pricing cycles may lead to temporary fluctuations in utilisation, the structural demand outlook remained intact, supporting a progressive ramp- up. In parallel, the Company strengthened multiple The transition also supported the Company’s positioning towards greater market leadership in key segments, supported by scale, reliability and product quality. Higher volumes are expec
The Company’s focus on operational efficiency and cost optimisation enabled it to maintain a relatively competitive cost of production. In addition, its diversified revenue mix across multiple products and end-use applications helped cushion the impact of demand softness in specific segments. While the broader industry slowdown did have an impact on overall performance during the year, these structural strengths help
The result is a lower capital intensity per new project and a reduced operating cost per unit of production. Backward integration into raw materials: By manufacturing Chlorine, Hydrogen and Caustic Soda, Epigral reduced a dependence on external suppliers for key intermediates. This mitigated supply chain disruptions, improved input cost visibility, enhanced negotiation power and protects margins during global price s
This transition is improving cost efficiency while significantly reducing emissions and wastewater generation, aligning with tightening environmental regulations. Pricing trends during FY 2025–26 remained regionally varied due to differences in feedstock costs, supply conditions, and demand dynamics across key markets. In India, the market is witnessing strong momentum, driven by infrastructure expansion, increasing
While navigating the chemical sector slowdown, Epigral extended from Balance Sheet strengthening to capacity-led expansion, laying the ground for sustainable growth. Epigral continued to reduce its Chlor- Alkali revenue exposure and increase its revenue share from derivatives and specialty products. The commissioning of the Chlorotoluenes value chain marked the Company’s decisive step into higher-value specialty deri
Five, India’s chemical demand continues to grow steadily, and the planned capacities will enable the Company to effectively support this rising domestic demand. In this scenario, marginal debt reduction would not have structurally enhanced the Company’s competitiveness. In contrast, downstream integration would (and will) deepen the Company’s moat and enhance long-term capital productivity.
However, once domestic customer approvals were secured, export scalability became feasible due to the following reasons: Excessive China dependence risk among global buyers Increased diversification away from single-origin sourcing Cost competitiveness from integration Cost structure advantage: Epigral’s integration helped lower variable costs and improved operating leverage, enabling export pricing flexibility
It is also among the largest integrated players with a significant captive consumption of chlorine and hydrogen, which enhances cost efficiency and reduces external dependence. endurance as product approvals and market adoption progress gradually. In addition, specialty intermediates are generally approval-driven products.
ECH continues to benefit from demand in epoxy resins, wind energy, automotive components and infrastructure. CPVC demand is supported by urbanisation, housing development, plumbing upgrades and regulatory standards. Moreover, economies of scale will progressively strengthen our competitiveness as utilisation levels rise.
Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) By adopting the Extended Producer Responsibility (EPR) framework, we actively facilitate the recovery and responsible management of plastics at the end of their lifecycle, thereby contributing to the reduction of plastic waste and supporting the transition tow
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…